About: Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol® (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol® (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol® (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model
Creator	Kumaki, Yohichi Barnard, Dale Salazar, Andres Wandersee, Miles
Source	Elsevier; Medline; PMC
abstract	Abstract Hiltonol®, (Poly IC:LC), a potent immunomodulator, is a synthetic, double-stranded polyriboinosinic-polyribocytidylic acid (poly IC) stabilized with Poly-L-lysine and carboxymethyl cellulose (LC). Hiltonol® was tested for efficacy in a lethal SARS-CoV-infected BALB/c mouse model. Hiltonol® at 5, 1, 0.5 or 0.25 mg/kg/day by intranasal (i.n.) route resulted in significant survival benefit when administered at selected times 24 h prior to challenge with a lethal dose of mouse-adapted severe acute respiratory syndrome coronavirus (SARS-CoV). The infected BALB/c mice receiving the Hiltonol® treatments were also significantly effective in protecting mice against weight loss due to infection (p < 0.001). Groups of 20 mice were dosed with Hiltonol® at 2.5 or 0.75 mg/kg by intranasal instillation 7, 14, and 21 days before virus exposure and a second dose was given 24 h later, prophylactic Hiltonol® treatments (2.5 mg/kg/day) were completely protective in preventing death, and in causing significant reduction in lung hemorrhage scores, lung weights and lung virus titers. Hiltonol® was also effective as a therapeutic when give up to 8 h post virus exposure; 100% of the-infected mice were protected against death when Hiltonol® was administered at 5 mg/kg/day 8 h after infection. Our data suggest that Hiltonol® treatment of SARS-CoV infection in mice leads to substantial prophylactic and therapeutic effects and could be used for treatment of other virus disease such as those caused by MERS-CoV a related coronavirus. These properties might be therapeutically advantageous if Hiltonol® is considered for possible clinical use.
has issue date	2017-03-31(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2016.12.007
bibo:pmid	27956136
has license	els-covid
sha1sum (hex)	311c9666e5681a3fef58ca294dea72e708f08219
schema:url	https://doi.org/10.1016/j.antiviral.2016.12.007
resource representing a document's title	Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol® (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model
has PubMed Central identifier	PMC7113886
has PubMed identifier	27956136
schema:publication	Antiviral Research
resource representing a document's body	covid:311c9666e5681a3fef58ca294dea72e708f08219#body_text
is schema:about of	named entity 'weight loss' named entity 'infection' named entity 'advantageous' named entity 'leads' named entity 'infection' named entity 'efficacy' named entity 'times' named entity 'SARS-CoV' named entity 'lethal' named entity 'Poly' named entity 'IMMUNOMODULATOR' named entity 'THERAPEUTIC' named entity '28P' named entity 'INFECTION' named entity 'ADMINISTERED' named entity 'PROPHYLACTIC' named entity 'UP TO' named entity 'DUE TO' named entity 'BENEFIT' named entity 'CLINICAL' named entity '282' named entity 'MICE' named entity 'USE' named entity 'COMPLETELY' named entity 'CAUSING' named entity 'LEADS' named entity 'ROUTE' named entity 'MOUSE MODEL' named entity 'PROPERTIES' named entity 'MG%' named entity 'INSTILLATION' named entity 'LUNG' named entity 'SECOND' named entity 'PRIOR TO' named entity 'LUNG HEMORRHAGE' named entity 'SUGGEST' named entity 'DAY' named entity '0.75' named entity '0.001' named entity 'COULD BE' named entity 'USED' named entity 'THESE' named entity 'INFECTED' named entity 'CAUSED BY' named entity 'DAYS' named entity 'SIGNIFICANT' named entity 'ACID' named entity 'DOUBLE' named entity 'OUR' named entity 'DATA' named entity 'LETHAL' named entity '2.5' named entity 'RECEIVING' named entity 'VIRUS DISEASE' named entity 'GIVEN' named entity 'INFECTED' named entity 'ADAPTED' named entity 'HILTONOL' named entity 'PREVENTING' named entity 'DEATH' named entity 'WEIGHTS' named entity 'TREATMENT' named entity 'POSSIBLE' named entity '0.5' named entity 'RELATED' named entity 'EFFICACY' named entity 'GROUPS' named entity '100%' named entity 'INTRANASAL' named entity '0.25' named entity 'INTRANASAL ADMINISTRATION' named entity 'SARS-COV' named entity 'HILTONOL' named entity 'PROPHYLACTIC' named entity 'BALB' named entity 'SURVIVAL' named entity 'EFFECTS' named entity 'IMMUNOMODULATOR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software